Braeburn Pharmaceuticals

Closed portfolio snapshot

According to ClinicalTrials.gov-derived indexes, Braeburn Pharmaceuticals sits in the upper quartile of US sponsors by registered trial count (#1,604 of 15,742 sponsors by registered trial count).

8 total trials none currently recruiting 8 completed upper quartile by trial count

Braeburn Pharmaceuticals: 8 sponsored US clinical trials, none currently recruiting.

Braeburn Pharmaceuticals sponsors 8 registered US clinical trials on ClinicalTrials.gov, none currently recruiting, and 8 completed. 4 of these trials are in Phase 3-4 (later-stage) and 4 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Schizophrenia, with 2 trials.

Upper-quartile sponsor footprint

Braeburn Pharmaceuticals sits in the upper quartile of the sponsor corpus (#1,604 of 15,742 sponsors by registered trial count) - denser than most sponsors, still short of the top-decile hubs.

Indexed trials (enrollment closed)

8 total, page 1 of 1

COMPLETED Phase 3

Buprenorphine (CAM2038) in Subjects With a Recent History of Moderate to Severe Chronic Low Back Pain

NCT02946073
COMPLETED Phase 1

Study to Evaluate D2 Receptor Occupancy Following Single Intravenous Administration of ATI-9242

NCT02824666
COMPLETED Phase 3

Safety and Tolerability of Risperidone Implants

NCT02773576
COMPLETED Phase 3

Clinical Trial of CAM2038, Long-acting Subcutaneous Buprenorphine Injections for Treatment of Patients With Opioid Dependence

NCT02651584
COMPLETED Phase 3

Long-Term Safety Study of Buprenorphine (CAM2038) in Adult Outpatients With Opioid Use Disorder

NCT02672111
COMPLETED Phase 2

Study in Stabilized Schizophrenic Patients to Evaluate the Pharmacokinetics of Risperidone and 9-Hydroxy (OH)-Risperidone When Risperidone is Administered From a Polyurethane Implant

NCT02658357
COMPLETED Phase 2

A Multiple Dose Opioid Challenge Study

NCT02611752
COMPLETED Phase 2

Phase II Pharmacokinetics Study of CAM2038

NCT02710526

Phase Distribution

PhaseTrial count
Phase 1 1
Phase 2 3
Phase 3 4

Therapeutic Areas

Schizophrenia 2
Opioid Use Disorder 2
Schizoaffective Disorder 1
Chronic Pain 1

How the Braeburn Pharmaceuticals archive is shaped

8 indexed studies, none listed as recruiting (0% open); 8 completed (100%).

Phase mix: 4 late (III/IV) vs 4 early (I/II) (balanced across stages).

Top condition: Schizophrenia (2 trials), 3 others listed.

How to read a closed sponsor archive

When recruiting_count is zero, the indexed set is completed or otherwise not open. Phase tilt still describes where archived studies sat on the investigational pathway. Re-check ClinicalTrials.gov before acting.

Braeburn Pharmaceuticals: archived-pipeline peers nationwide

Peers matched on 8 indexed studies with no current recruiting: volume and archive shape, not condition overlap.

Braeburn Pharmaceuticals sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot). 2×2 strategic matrix plotting 9 entities by Total trials (X) and Recruiting share (Y), with a crosshair dividing the plot into four quadrants. Higher volume & more openFocused & more openHigher volume, mostly closedSmaller & mostly closed 051015 0%10%20%30%40% Total trials Recruiting share Braeburn PharmaceuticalsAB ScienceAbbott Point of CareAbeona TherapeuticsAcademisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)10xBio22nd Century Group23andMe3-C Institute for Social Development
Braeburn Pharmaceuticals sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot).

Braeburn Pharmaceuticals sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.

Sponsors near 8 archived trials

Sponsors with similar archive density (± trial count)

Related

Read our methodology - how this data is sourced, computed, and verified.

What to do with this Braeburn Pharmaceuticals page

8 registered trials is a research-attention snapshot, not an endorsement of Braeburn Pharmaceuticals or any single study.

  • None of Braeburn Pharmaceuticals's trials are currently recruiting in this registry; that can change as new trials post, or check the broader research index. Browse research indexes
  • Schizophrenia is the condition Braeburn Pharmaceuticals studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Schizophrenia trials
  • Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Braeburn Pharmaceuticals pipeline card: 8 registered trials from official public datasets.Report a data error.